Intraperitoneal hyperthermic chemotherapy using carboplatin: A phase I analysis in ovarian carcinoma

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 207-210

  Lentz, Samuel S ^a   Miller, Brigitte E ^a   Kucera, Gregory L ^a   Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Hyperthermia; Intraperitoneal therapy; Ovarian carcinoma

Indexed keywords

CARBOPLATIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LAPAROTOMY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PEROPERATIVE CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND LOOK SURGERY;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEMATOLOGIC DISEASES; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 34250198639     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.022     Document Type: Article

References (22)

1. Alberts D.S., Lui P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 26 (1996) 1950-1955
2. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 4 (2001) 1001-1007
3. Armstrong D.K., Bundy B.N., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
4. Speyer J.L., Beller U., Colombo N., Sorich J., Wernz J.C., Hochster H., et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J. Clin. Oncol. 8 8 (1990) 1335-1341
5. Pfeiffer P., Bennedaek O., and Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol. Oncol. 36 (1990) 306-311
6. Glehen O., Mohamed F., and Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 5 4 (2004) 219-228
7. Sugarbaker P.H. A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin. Oncol. 32 6 Suppl 9 (2005) S68-S73
8. Oleson J.R. Hyperthermia. In: Devita V.T., Hellman S., and Rosenburg S.A. (Eds). Cancer, principles and practice of Oncology (1989), JB Lippincott Company, Philadelphia 2426-2435
9. Giovanella B.C., Stehlin Jr. J.S., and Morgan A.C. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 36 (1976) 3944-3950
10. Kimura E., and Howell S.B. Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line. Cancer Chemother. Pharmacol. 32 (1993) 419-424
11. Los G., van Vugt M.J., and Pinedo H.M. Response of peritoneal solid tumuors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br. J. Cancer 69 (1994) 235-241
12. Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol. Oncol. 94 2 (2004) 325-332
13. Steller M.A., Egorin M.J., Trimble E.L., Bartlett D.L., Zuhowski E.G., Alexander H.R., et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol. 43 2 (1999) 106-114
14. Gadducci A., Sartori E., Landoni F., Zola P., Maggino T., Maggioni A., et al. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J. Clin. Oncol. 23 4 (2005) 751-758
15. Elferink F., van der Vijgh W.J., Klein I., ten Bokkel Huinink W.W., Dubbelman R., and McVie J.G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21 1 (1988) 57-60
16. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47 2 (1987) 414-418
17. Los G., van Vugt M.J., den Engelse L., and Pinedo H.M. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem. Pharmacol. 46 7 (1993) 1229-1237
18. Vasanthan A., Mitsumori M., Park J.H., Zhi-Fan Z., Yu-Bin Z., Oliynychenko P., et al. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int. J. Radiat. Oncol. Biol. Phys. 61 1 (2005) 145-153
19. Wren J. Evaluation of three temperature measurement methods used during microwave thermotherapy of prostate enlargement. Int. J. Hypertherm. 20 3 (2004) 300-316
20. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis Jr. J.L., et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J. Clin. Oncol. 10 9 (1992) 1485-1491
21. Glehen O., Kwiatkowski F., Sugarbaker P.H., Elias D., Levine E.A., De Simone M., et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J. Clin. Oncol. 22 16 (2004) 3284-3292
22. Shen P., Levine E.A., Hall J., Case D., Russell G., Fleming R., et al. Factors predicting survival following intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch. Surg. 138 1 (2003) 26-33